Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
- Latest News
- Most Popular
- Hitting Home Runs & Grand Slams, Not Loud Outs
- RTI: Do Stocks Tank When QE Ends?
- 3 Top-Ranked Consumer ETFs to Buy Now
- This Week's Aggressive Growth Stocks
- Who Wants to Keep "Too Big to Fail" Alive?
- Debt-Ceiling Alarm Bell Tolls
- Avoid These 3 Eurozone ETFs This Summer
- RTI: When Will We Finally See a Pullback?
- Top Stocks with Big Potential Catch-Up Moves
- AWS 5/22: Will Bernanke Show His Hand?
- PFP 5/22: Singular Stock Focus Continues
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 05/22/2013
| Company Name | Symbol | %Change |
|---|---|---|
| ALLIANCE FIB | AFOP | 9.31% |
| SONIC FOUNDR | SOFO | 7.77% |
| TRI TECH HOL | TRIT | 6.62% |
| A M R CP | AAMRQ | 4.52% |
| FLOWERS FOOD | FLO | 4.31% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
• Dell Inc. (NASDAQ:DELL) reported Q1 EPS of $0.55, higher than the Zacks Consensus Estimate of $0.43 per share. Revenue for the quarter edged up 1% year-over-year to $15.02 billion, falling short of the Zacks Consensus Estimate of $15.457 billion
• Share prices of US listed Allied Irish Banks, PLC. (NYSE:AIB) rose 13.33% to close at $3.06 after the banking company unveiled a new structure and top management team
• Leerink Swann initiated coverage on shares of Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) with an "Outperform" rating and a valuation call of $12 to $14 per share
• Share prices of elong, Inc. (NASDAQ:LONG) increased 56.72% on news that China‘s Tencent Holdings has bought a 16% stake in the company for $84.4 million
• Shares of FairPoint Communications, Inc. (NASDAQ:FRP) fell more than 40% to close at $9.59. Although the company posted first quarter profits, its revenues were flat compared to the prior year
• Analysts at Madison Williams initiated coverage on Linn Energy, LLC (NASDAQ:LINE) with a “Buy” rating and a target price of $45.00
• Analysts at Goldman Sachs (NYSE:GS) initiated coverage on MAKO Surgical (NASDAQ:MAKO) with a “Buy” rating
• Analysts at Boenning & Scattergood initiated coverage on Nektar Therapeutics (NASDAQ:NKTR) with an “Outperform” rating and a target price of $15.00
• Analysts at Oppenheimer analysts initiated coverage on Oncolytics Biotech, Inc. (NASDAQ:ONCY) setting a “perform” rating
• Analysts at ThinkEquity initiated coverage on Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR) with a “Buy” rating and a target price of $18.00
Read the full reports :
Analyst Report on DELL
Snapshot Report on ANTH
Snapshot Report on LONG
Snapshot Report on FRP
Snapshot Report on LINE
Analyst Report on GS
Snapshot Report on MAKO
Snapshot Report on NKTR
Snapshot Report on ONCY
Analyst Report on OPTR